Greenland Mines (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.
This development is significant because it strengthens Greenland Mines' position in the emerging field of gene therapy for neurodegenerative conditions, which affect millions worldwide. The patent provides a competitive advantage by protecting the company's proprietary technology in a key market, potentially paving the way for future clinical trials and commercialization. The advancement of KLTO-101 and KLTO-202 into manufacturing stages indicates progress toward regulatory filings, which could bring these therapies closer to patients.
To view the full press release, visit: https://ibn.fm/x2pHA. The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML.
Greenland Mines Ltd. is a Nasdaq-listed company with two operating divisions: Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities.
